News

1 5 9 12 13 14 15 16
NEWS

SOTIO receives orphan-drug designation for Ovarian Active Cellular Immunotherapy

SOTIO has received orphan-drug designation from the U.S. Food and Drug Administration (FDA) for the active cellular immunotherapy (ACI) DCVAC/OvCa.

NEWS

SOTIO at ASCO Annual Meeting 2013

At this years annual meeting of the American Society of Clinical Oncology (ASCO) held from May 31 to June 4, in Chicago, Illinois; SOTIO will for the first time ever introduce itself to the worldwide oncology community.

NEWS

SOTIO receives EMA approval

SOTIO receives European Medicines Agency approval to initiate Phase III VIABLE Clinical Trial of DCVAC/PCa, an active cellular immunotherapy drug targeted for prostate cancer patients. Lead Candidate from SOTIO’s DCVAC program.